Department of Ophthalmology, University of California-Irvine, Irvine, California, United States of America.
Department of Ophthalmology, Children's Hospital of University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
PLoS One. 2020 Sep 17;15(9):e0238727. doi: 10.1371/journal.pone.0238727. eCollection 2020.
Female mice have been found to be resistant to streptozotocin (STZ)-induced diabetes, and pre-clinical research related to diabetic complications commonly omits females. The purpose of this study was to develop a method to induce diabetes in female mice, and to determine if retinas of diabetic female mice develop molecular changes and histopathological abnormalities comparable to those which develop in male diabetic mice.
To induce diabetes, animals of both sexes received daily intraperitoneal (i.p.) injection of STZ for 5 consecutive days at 55 mg/kg BW (a dose that is known to induce diabetes in male mice) or for females, 75 mg/kg BW of STZ. Retinal abnormalities that have been implicated in the development of the retinopathy (superoxide generation and expression of inflammatory proteins, iNOS and ICAM-1) were evaluated at 2 months of diabetes, and retinal capillary degeneration was evaluated at 8 months of diabetes.
Daily i.p. injection of STZ for 5 consecutive days at a concentration of 55 mg/kg BW was sufficient to induce diabetes in 100% of male mice, but only 33% of female mice. However, females did become hyperglycemic when the dose of STZ administered was increased to 75 mg/kg BW. The resulting STZ-induced hyperglycemia in female and male mice was sustained for at least 8 months. After induction of the diabetes, both sexes responded similarly with respect to the oxidative stress, expression of iNOS, and degeneration of retinal capillaries, but differed in the limited population evaluated with respect to expression of ICAM-1.
The resistance of female mice to STZ-induced diabetes can be overcome by increasing the dose of STZ used. Female mice can, and should, be included in pre-clinical studies of diabetes and its complications.
研究发现雌性小鼠对链脲佐菌素(STZ)诱导的糖尿病具有抗性,而与糖尿病并发症相关的临床前研究通常忽略了雌性。本研究旨在开发一种诱导雌性小鼠发生糖尿病的方法,并确定雌性糖尿病小鼠的视网膜是否会发生与雄性糖尿病小鼠相似的分子变化和组织病理学异常。
为了诱导糖尿病,雌雄动物均接受连续 5 天每天腹腔内(i.p.)注射 STZ,雄性动物的剂量为 55mg/kgBW(已知该剂量可诱导雄性小鼠发生糖尿病),而雌性动物的剂量为 75mg/kgBW 的 STZ。在糖尿病发病 2 个月时,评估与视网膜病变发展相关的视网膜异常(超氧化物生成和炎症蛋白 iNOS 和 ICAM-1 的表达),并在糖尿病发病 8 个月时评估视网膜毛细血管退化。
每天腹腔内注射 STZ,浓度为 55mg/kgBW,连续 5 天,足以使 100%的雄性小鼠发生糖尿病,但只有 33%的雌性小鼠发生糖尿病。然而,当 STZ 剂量增加到 75mg/kgBW 时,雌性小鼠也会发生高血糖。在雌性和雄性小鼠中,由此诱导的 STZ 诱导的高血糖至少持续了 8 个月。在糖尿病诱导后,两性在氧化应激、iNOS 表达和视网膜毛细血管退化方面的反应相似,但在评估的有限人群中,ICAM-1 的表达存在差异。
通过增加 STZ 的使用剂量,可以克服雌性小鼠对 STZ 诱导的糖尿病的抗性。在糖尿病及其并发症的临床前研究中,应该纳入雌性小鼠。